Provided by Tiger Trade Technology Pte. Ltd.

Voyager Therapeutics

3.96
-0.0300-0.75%
Post-market: 3.960.00000.00%19:23 EDT
Volume:462.54K
Turnover:1.80M
Market Cap:236.01M
PE:-1.94
High:3.96
Open:3.91
Low:3.80
Close:3.99
52wk High:5.55
52wk Low:2.65
Shares:59.60M
Float Shares:47.32M
Volume Ratio:0.90
T/O Rate:0.98%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.0400
EPS(LYR):-1.1272
ROE:-48.29%
ROA:-24.86%
PB:1.20
PE(LYR):-3.51

Loading ...

Voyager Therapeutics CEO Alfred Sandrock Reports Sale of Common Shares

Reuters
·
Feb 12

Voyager Therapeutics to Present at Multiple Major Investor Conferences

Reuters
·
Feb 09

Analysts Offer Insights on Healthcare Companies: Voyager Therapeutics (VYGR), InflaRx (IFRX) and Verastem (VSTM)

TIPRANKS
·
Feb 05

Voyager Therapeutics Files Initial Beneficial Ownership Statement for Gregory L. Shiferman, SVP and General Counsel

Reuters
·
Jan 09

Voyager Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Nov 13, 2025

Analysts Offer Insights on Healthcare Companies: Voyager Therapeutics (VYGR) and Skye Bioscience (SKYE)

TIPRANKS
·
Nov 12, 2025

Voyager Therapeutics price target lowered to $25 from $30 at H.C. Wainwright

TIPRANKS
·
Nov 12, 2025

Voyager Therapeutics Inc : H.c. Wainwright Cuts Target Price to $25 From $30

THOMSON REUTERS
·
Nov 12, 2025

Voyager Therapeutics (VYGR) Receives a Buy from Wells Fargo

TIPRANKS
·
Nov 12, 2025

Analysts Offer Insights on Healthcare Companies: Alpha Teknova (TKNO), Voyager Therapeutics (VYGR) and Terns Pharmaceuticals (TERN)

TIPRANKS
·
Nov 11, 2025

Wedbush Keeps Their Buy Rating on Voyager Therapeutics (VYGR)

TIPRANKS
·
Nov 11, 2025

Voyager Therapeutics files $400M mixed securities shelf

TIPRANKS
·
Nov 11, 2025

Voyager Therapeutics Inc Files for Mixed Shelf Offering of up to $400 Mln- SEC Filing

THOMSON REUTERS
·
Nov 11, 2025

Voyager Therapeutics price target lowered to $11 from $12 at Leerink

TIPRANKS
·
Nov 11, 2025

Voyager Therapeutics, Transition Bio entered into drug discovery collab

TIPRANKS
·
Nov 10, 2025

Biotech firm Voyager's Q3 collaboration revenue drops, net loss widens

Reuters
·
Nov 10, 2025

Voyager Therapeutics and Transition Bio Partner to Develop Small Molecule Therapies for ALS and FTD

Reuters
·
Nov 10, 2025

Voyager Therapeutics reports third quarter revenue of $13.4 million

Reuters
·
Nov 10, 2025

BRIEF-Voyager Therapeutics Q3 Collaboration Revenue USD 13.365 Million

Reuters
·
Nov 10, 2025

Voyager Therapeutics Q3 Operating Income USD -30.594 Million

THOMSON REUTERS
·
Nov 10, 2025